As part of Roche's Technology Transfer Initiative, these companies will be provided free of charge with the technical expertise and guidance to manufacture generic HIV medicine, based upon the processes to produce saquinavir, Roche's 2nd line1 HIV medicine.
To read the rest of the article, click here